You need to be logged in to view this video

Lixte's LB-100: A Breakthrough in Targeted Cancer Therapy

Released on Wednesday, July 14, 2021BIOTECH
A major driver of cancer is defects in the switches that turn the biochemical pathways in cells on and off. Most cancer research over the past 30 years has focused on the on switches because the off switches, especially the master off switch protein phosphatase (PP2A), were believed to cause intolerable toxicity in patients. Lixte has achieved a breakthrough with its novel, first-in-class lead compound, PP2A inhibitor LB-100, by demonstrating that it is readily tolerated in cancer patients at doses associated with anti-cancer activity. This innovative approach encourages cancer cells, weakened by chemo or other cancer therapies, to continue to replicate, leading to the more efficient death and elimination of those cells from the body.

John Kovach
Lixte Biotechnology Holdings, Inc., CEO and Founder

Trending Now


Filter By Category
Filter By Keywords
Loading...
Live Now

Accredited Investors Virtual Expo

July 27 - 29, 2021